Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

By G. Musso, R. Gambino, M. Cassader, G. Pagano. Annals medicus, 2011

1,321 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Surgery

View Paper: https://www.semanticscholar.org/paper/cc03ccb7b30dccf002570cefad7dcc725c4bd72b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Z. Younossi
2. G. Targher
3. M. Rinella
4. K. Cusi
5. A. Sanyal
6. Christopher D. Byrne
7. E. Brunt
8. J. Lavine

In Hepatology

1. Z. Younossi
2. M. Rinella
3. G. Targher
4. K. Cusi
5. A. Sanyal
6. Christopher D. Byrne
7. E. Brunt
8. A. Diehl

In Surgery

1. M. Nauck
2. Christopher D. Byrne
3. Silvio E. Inzucchi
4. Z. Goodman
5. E. Ferrannini
6. John B. Buse
7. G. Targher

Citations in the corpus

• Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality (2011, background): “In summary, our data confirm that patients with NASH are at high risk for LRM.(1-14,21-30) We have also shown that a certain degree of agreement exists between all four sets of pathologic criteria for NASH.”
• The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (2012, background): “Natural History The evolution of hepatic histologic changes in patients with NAFL and NASH has been investigated by several studies, but these generally included smaller number of patients and had relatively modest duration of follow-up.(4,7) Nonetheless, it is generally agreed that patients with si”
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach (2012, background): “There is preliminary evidence that patients with fatty liver may benefit from treatment with pioglitazone (45,127,128).”
• EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. (2015, background): “In patients with NAFLD, the NAFLD fibrosis score [40] is currently the most studied [85,113–118] and validated biomarker [119].”
• NAFLD: a multisystem disease. (2015, background): “, a recent meta-analysis showed that NAFLD increased overall mortality by 57% mainly from liverrelated and CVD causes, and increased risk of incident T2DM by approximately twofold [6].”